
|Articles|February 16, 2021
Supplements and Featured Publications
- Current and Emerging Trends in Chronic Myeloid Leukemia
- Volume 1
- Issue 1
Current and Future Trends in Chronic Myeloid Leukemia
Advertisement
This publication includes a summary of data on therapeutic agents for the current and future treatment landscape of chronic myeloid leukemia. Hematologic oncology experts provide key insights on approaching disease management, including a discussion on treatment options through later-line settings.
Articles in this issue
about 5 years ago
Dr. Cortes on the Future of Ponatinib in CML Treatmentabout 5 years ago
Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CMLabout 5 years ago
Dr. Cortes on Navigating Among Frontline TKIs in the CML Paradigmabout 5 years ago
Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CMLabout 5 years ago
Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CMLabout 5 years ago
Dr. Sweet on Treatment Selection With TKIs in CMLAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5



































